Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma

Sep 24, 2026

Upload by Kyle

Pan-cancer analysis investigates IBSP, a small integrin-binding ligand N-linked glycoprotein (SIBLING) family member, whose role in tumor prognosis and immunotherapy remains unclear. The study evaluates tumorigenesis, genomic heterogeneity, methylation changes, immune infiltration, and therapy response across cancer types, and builds an osteosarcoma (OS) risk score model using IBSP co-expression genes. Findings show IBSP upregulation versus paired normal tissues, with strong associations to prognosis, stage, diagnostic accuracy, methylation, immune checkpoint features, and in vitro promotion of OS proliferation, migration, and invasion. Results support IBSP as a prognostic biomarker and immunotherapy target in pan-cancer.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

Background

Methods

Results

Conclusions

Introduction

TYPE Original Research PUBLISHED 29 June 2023 DOI 10.3389/fimmu.2023.1188256 OPEN ACCESS EDITED BY Takaji Matsutani, Repertoire Genesis, Inc., Japan REVIEWED BY Hanchen Xu, Longhua Hospital Shanghai University of Traditional Chinese Medicine, China Fei Peng, University of Texas Southwestern Medical Center, United States *CORRESPONDENCE Jun Cheng [chengjundoctor@163.com](chengjundoctor@163.com)[ ](chengjundoctor@163.com)Youwen Deng [drywdeng@csu.edu.cn](drywdeng@csu.edu.cn) RECEIVED 17 March 2023 ACCEPTED 07 June 2023 PUBLISHED 29 June 2023 CITATION Pan B, Cheng X, Tan W, Liu R, Wu X, He J, Fan Q, Zhang Y, Cheng J and Deng Y (2023) Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma. Front. Immunol. 14:1188256 . doi: 10.3389/fimmu.2023.1188256 COPYRIGHT © 2023 Pan, Cheng, Tan, Liu, Wu, He, Fan, Zhang, Cheng and Deng. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma Boyu Pan 1, Xiaoyun Cheng 2,3, Wei Tan 1, Renfeng Liu 1, Xin Wu 1, Jinpeng He 1, Qizhi Fan 1, Yan Zhang 3, Jun Cheng 1,4* and Youwen Deng 1* 1 Department of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China, 2 Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China, 3 Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China, 4 Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Background: IBSP is a member of the small integrin-binding ligand N-linked glycoprotein (SIBLING) family that plays a vital role in bone formation, renewal and repair. Emerging evidence revealed that IBSP participated in the tumorigenesis and progression in some cancers. However, its signiﬁcance in tumour prognosis and immunotherapy is still unknown. Methods: In the current study, we studied the role of IBSP in tumorigenesis, tumor diagnosis, genomic heterogeneity, methylation modiﬁcations, immune inﬁltration, and therapy response in pan-cancer. In addition, we constructed a risk score model to assessed the prognostic classiﬁcation efﬁciency of IBSP using the co-expression genes of IBSP in osteosarcoma (OS), and analyzed the expression and role of IBSP in OS through a series of assays in vitro. Results: IBSP was upregulated in various cancers compared to the paired normal tissues, and it was strongly correlated with the prognosis, pathological stage, diagnostic accuracy, genomic heterogeneity, methylation modiﬁcation, immune inﬁltration, immune and checkpoint. Moreover, the predictive model we established in combination with the clinical characteristics of OS patients showed high survival predictive power in these individuals. The assays in vitro showed that IBSP promoted the proliferation, migration and invasion of OS cells, which further conﬁrmed IBSP’s role in cancers. Conclusions: Our research revealed the multifunctionality of IBSP in the tumorigenesis, progression and therapy in various cancers, which demonstrated that IBSP may serve as a potential prognostic biomarker and a novel immunotherapy target in pan-cancer. KEYWORDS IBSP, pan-cancer, prognosis, immunotherapy, osteosarcoma Frontiers in Immunology 01 [frontiersin.org](frontiersin.org) 1 Introduction Osteosarcoma

FAQs

What is the main purpose of the study on IBSP?

To determine whether IBSP has prognostic value and immunotherapeutic relevance across multiple cancer types, including osteosarcoma.

Which aspects of cancer biology were analyzed in the pan-cancer study?

The study examined tumorigenesis and diagnosis, genomic heterogeneity, methylation modifications, immune infiltration, and therapy response.

What key results were observed regarding IBSP expression and clinical associations?

IBSP was upregulated in multiple cancers compared with paired normal tissues and strongly correlated with prognosis, pathological stage, diagnostic accuracy, genomic heterogeneity, methylation, and immune-related features.

How did the osteosarcoma experiments support IBSP’s potential role?

The OS risk score model showed strong survival predictive power, and in vitro assays indicated IBSP promoted OS cell proliferation, migration, and invasion.

Sep 24, 2026

Upload by Kyle